Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version (GlobeNewswire)

Mainz Biomed N.V., a company specializing in early cancer detection, has reported growing demand for its enhanced ColoAlert colorectal cancer (CRC) screening product, launched in July 2024. This advanced DNA biomarker-based test is being adopted by laboratory partners across Europe and select international markets. One of the first adopters is GANZIMMUN Diagnostics, a leading German laboratory, which will fully implement the enhanced ColoAlert by early 2025. The updated product features improved sample processing and usability, reducing retesting rates and offering quicker results, typically within 2–3 days.